YHYue Hu

Yue Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yue Hu has a total of 142 co-authors. Here are the top co-authors by number of shared publications:

  • Li Jiang

    22 shared publications
  • Xiaoling Peng

    9 shared publications
  • Hao Zheng

    Department of Neurology Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders Chongqing China

    5 shared publications
  • Li Jiang

    Department of Neurology, Children's Hospital of Chongqing Medical University, China; National Clinical Research Center for Child Health and Disorders (Chongqing), China; Ministry of Education Key Laboratory of Child Development and Disorders, China; China International Science and Technology Cooperation base of Child development and Critical Disorders, China; Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, China

    5 shared publications
  • Xiao-Ling Peng

    Guangdong Provincial Key Laboratory of Interdisciplinary Research and Application for Data Science, BNU-HKBU United International College, Zhuhai, China

    5 shared publications
  • Jin Chen

    Department of Neurology, Children’s Hospital of Chongqing Medical University, Chongqing, China

    4 shared publications

Latest Publications

  • Global prevalence of epilepsy and temporal trends, 1980–2025: a systematic review and meta-analysis

    by Xiaoyu Zhao, Jiali Dai, Li Jiang, Yue Hu

    Objective To synthesize population-based studies of epilepsy prevalence published between 1980 and 2025, estimate pooled global prevalence, characterize regional differences, quantify temporal trends, and examine the influence of study characteristics and development indicators (Human Development Index [HDI] and Socio-demographic Index [SDI]). Methods We systematically searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Library for observational studies published from January 1, 1980 to December 31, 2025. Random-effects meta-analysis was used to pool prevalence estimates. Pre-specified subgroup analyses were conducted by geographical region, survey period, study design, data source, sample size, and HDI/SDI strata. Methodological subgroup analyses and sensitivity analyses were further performed to assess the robustness of the pooled estimates. Temporal patterns were assessed using regression-based β trend analysis across study survey years and estimated annual percentage change (EAPC) derived from the Global Burden of Disease (GBD) database. Results We included 216 studies comprising 278,651,975 participants and 2,114,157 epilepsy cases. The pooled global prevalence was 7.57 per 1,000 population (95% confidence interval [CI], 6.78–8.45). Literature-based trend analysis suggested an increase in reported prevalence estimates from 1980 to 2025 (β = 0.206 per 1,000 population per year; P < 0.01). GBD-based analyses also showed an overall increase from 1990 to 2021 (EAPC = 0.102% per year), with significant increases during 1990–2009 but no significant change during 2010–2021. Prevalence differed significantly across geographical regions (P < 0.001), highest in Africa (10.67 per 1,000) and lowest in Asia (5.20 per 1,000). Prevalence was higher in low-HDI settings than in very high-HDI settings, but meta-regression did not support significant linear associations between prevalence and HDI or SDI (both P > 0.05). No significant sex difference was observed (P = 0.76). Sensitivity analyses supported the robustness of the main pooled estimate, and methodological subgroup analyses showed no major variation across prevalence definitions, case ascertainment methods, or diagnostic confirmation approaches. Conclusions Epilepsy prevalence remains high worldwide, with an overall increase in reported prevalence over the past four decades but a slower recent rise. Marked geographical disparities were observed, with higher reported prevalence in low-resource settings. Strengthening standardized epidemiological surveillance and improving access to diagnosis and treatment remain priorities, particularly in resource-limited regions.


  • Open Access

    Efficacy and Safety of Adjunctive Perampanel in Young Children (7–46 Months) With Drug‐Resistant Epilepsy: A Real‐World Study

    by Qiao Zeng, Xueqian Xia, Hao Zheng, Lu Yang, Li Jiang, Yue Hu

    Background: To evaluate the efficacy and safety of adjunctive perampanel (PER) in young children with drug‐resistant epilepsy (DRE) aged 7–46 months, and to identify predictors of treatment response in real‐world clinical practice. Methods: We conducted a nonrandomized, open‐label, single‐arm, self‐controlled real‐world study at the Children's Hospital of Chongqing Medical University between December 2020 and August 2024. Eighty‐seven children with DRE received PER as adjunctive therapy to existing antiseizure medications (ASMs). The primary endpoint was the responder rate (≥ 50% reduction in seizure frequency) at 3, 6, 9, and 12 months. Secondary endpoints included seizure freedom, treatment retention, and treatment‐emergent adverse events (TEAEs). Results: Responder rates were 39.5%, 46.9%, 43.2%, and 44.4% at 3, 6, 9, and 12 months, respectively. Responder rates were 50.0% in Dravet syndrome, 50.0% in Lennox–Gastaut syndrome, and 34.8% in infantile epileptic spasms syndrome. Children with genetic etiologies had a 51.7% responder rate, including 60.0% in those with SCN1A variants. Multivariable logistic regression identified perinatal brain injury as an independent predictor of favorable response, while concomitant use of three ASMs predicted poorer outcomes. Treatment retention rates were 87.4%, 69.0%, 59.8%, and 55.2% at 3, 6, 9, and 12 months. TEAEs occurred in 23.0% of patients, most commonly somnolence (11.5%) and irritability/aggressive behavior (9.2%); 4.6% discontinued due to TEAEs. Conclusion: Adjunctive PER demonstrated clinically meaningful efficacy and a favorable safety profile in young children with DRE, supporting its potential role as a broad‐spectrum ASM in this age group.

  • Clinical spectrum and treatment responses in

    by Xiao Xiao, Xiaoqi Chen, Hao Zheng, Miao Xiong, Yuhang Liu, Li Jiang, Yue Hu

  • Open Access

    A Predictive Model for Surgical Risk in Infants with Traumatic Subdural Effusion Integrating Neutrophil-to-Lymphocyte Ratio and Multimodal Clinical Characteristics

    by Ting Ting Jiang, Man Luo, Xiaoling Peng, Hu Yue

    Objective: To investigate the early predictive value of neutrophil-to-lymphocyte ratio (NLR) for surgical requirement in infants with traumatic subdural effusion (TSE).Methods: A single-center retrospective cohort study was conducted, enrolling 629 patients aged ≤6 months with isolated traumatic brain injury. NLR was calculated based on a complete blood count within 48 hours post-injury. Logistic and LASSO regression were used to screen for independent risk factors. Machine learning was employed to impute missing values for continuous variables. The association between NLR and subdural burr hole drainage was analyzed using the area under the receiver operating characteristic curve (AUC). Combined prediction models were constructed.Results: 52 cases (8.27%) required surgical intervention. Injury mechanism, seizure (P<0.001), shortened APTT (original P=0.02, after imputation P=0.03), and elevated NLR (original P=0.01, after imputation P=0.004) were independent risk factors for surgical requirement. The optimal cutoff value for NLR was 0.80 (original apparent AUC=0.73, after imputation cross-validated AUC=0.69). The surgery rate in the high-NLR group (≥0.80) (13.70%) was significantly higher than that in the low-NLR group (4.18%) and was more frequently associated with traffic accident injury (20.00% vs. 9.75%) and seizure (16.30% vs. 6.41%). The model combining NLR with injury mechanism, seizure, and APTT significantly improved predictive performance (original apparent AUC=0.84, after imputation cross-validated AUC=0.78).Conclusion: NLR, as a low-cost and available biomarker, can effectively predict surgical requirements in infants with TSE. When combined with clinical indicators, it significantly enhances risk stratification capability. Machine learning handling missing data can improve the reliability of predictive models.

  • Disease spectrum of nonconvulsive status epilepticus in children: A study based on clinical subtype characteristics and prognostic stratification

    by Lianqin Mo, Xiaoqi Chen, Lu Yang, Xiao Xiao, Peng Wu, Li Jiang, Yue Hu

    Objective: To investigate risk factors affecting the short‐ and long‐term prognosis of pediatric status epilepticus (SE) complicated by nonconvulsive status epilepticus (NCSE) during the disease course and to analyze the clinical heterogeneity of this group to effectively identify population characteristics and subgroups influencing prognosis. Methods: This study is a single‐center retrospective cohort study. Clinical data from 215 pediatric patients diagnosed with SE at Chongqing Medical University Children's Hospital between February 2005 and September 2024, who met the diagnostic criteria for NCSE during their illness, were included. Univariate analysis and multivariate logistic regression were employed to identify factors associated with short‐term and long‐term adverse outcomes. Hierarchical cluster analysis was conducted based on clinical characteristics. Results: The in‐hospital mortality rate was 3.3% (7/215), increasing to 6.0% (12/200) in long‐term follow‐up. The short‐term poor prognosis rate was 29.8% (64/215), while the long‐term poor prognosis rate was 20.5% (41/200). Multivariate analysis revealed that independent risk factors for poor short‐term prognosis included GCS scores of 3–8, global developmental delay, interictal EEG showing periodic discharges, and diffuse MRI abnormalities. Poor long‐term prognosis was primarily associated with GCS scores of 3–8, global developmental delay, and electroclinical syndromes. Further clinical phenotype clustering analysis revealed four heterogeneous subgroups: super‐refractory subgroup (characterized by profound impaired consciousness and diffuse brain injury), young‐age metabolic subgroup (age < 24 months with multifocal abnormalities), focal structural subgroup (manifesting as focal neurological deficits and structural etiology), and benign reactive subgroup (mild altered consciousness and treatment sensitivity). Significance: Level of consciousness, electroencephalogram (EEG), neurodevelopmental status, and electroclinical syndromes can serve as core indicators for prognostic stratification in children with NCSE; subtyping based on clinical features can effectively distinguish heterogeneous subgroups, providing a clinical phenotypic basis for individualized stratified diagnosis, treatment, and prognostic assessment of pediatric NCSE, thereby addressing the current lack of a multidimensional stratification framework in clinical practice.

  • Open Access

    Efficacy and Safety of Zonisamide Addition in Children With Developmental Epileptic Encephalopathy/Epileptic Encephalopathy: A Real‐World Study

    by Peijiao Liu, Li Zhang, Qiao Zeng, XiaoYu Zhao, Li Jiang, Yue Hu

    Objective: To evaluate the real‐world effectiveness and safety of adjunctive zonisamide in children with developmental epileptic encephalopathy/epileptic encephalopathy (DEE/EE), focusing on younger children and highly drug‐resistant cases. Methods: This open‐label, nonrandomized, self‐controlled, real‐world study included 127 children with DEE/EE at a single center from 2020 to 2025. The primary endpoint was the responder rate (≥ 50% seizure reduction) at 3, 6, 9, and 12 months, analyzed using last observation carried forward. Secondary endpoints included seizure freedom, retention, and adverse events (AEs). Multivariable analysis identified predictors of efficacy. Results: Responder rates were 51.2%, 55.3%, 53.7%, and 53.7% at 3, 6, 9, and 12 months, respectively. Seizure‐free rates were 23.6%, 26.8%, 24.4%, and 27.6%. Efficacy was consistent across age and etiology. Female gender (OR = 3.00) and fewer prior anti‐seizure medications (OR = 0.77) independently predicted 12‐month response. Among children failing ≥ 5 prior medications, 44.3% responded, and 20.0% achieved seizure freedom. The 12‐month retention rate was 81.9%. AEs occurred in 14.2%, most commonly reduced appetite (7.9%); most were tolerable. Conclusion: Adjunctive zonisamide provides sustained efficacy and favorable tolerability in children with DEE/EE, including young children < 6 years and highly drug‐resistant cases. Gender and prior treatment history predict long‐term efficacy, supporting its reliable risk–benefit profile for refractory epilepsy.


  • Specialization challenges and improvement strategies in pediatric epilepsy diagnosis and treatment under the leadership of tertiary hospitals: A multi‐center cross‐sectional survey in Chongqing

    by Kaiyun Cao, Wei Liu, Yansen Jing, Qing Liu, Yaming Wang, Shan Yang, Wanyi Zhang, Li Jiang, Yue Hu

    Objective: To analyze the current state of primary pediatric epilepsy care, providing evidence for regional capacity‐building strategies. Methods: The cross‐sectional survey design was adopted to assess the epilepsy diagnostic and therapeutic capabilities of pediatric physicians from 37 medical institutions in the nine main urban districts and surrounding counties of Chongqing. Results: Tertiary (56.8%, 21/37) and general hospitals (75.7%, 28/37) dominated healthcare, yet pediatric neurology lagged: only 48.7% (18/37) had dedicated teams. Key technologies like Video‐EEG (43.2%) and genetic testing (54.1%) were underutilized; novel therapies (ketogenic diet 13.5%, neuromodulation 8.1%) were rarely applied. The median annual outpatient volume was 50 cases, and 33.3% of hospitals achieved >50% seizure freedom rate, yet 20.8% had >15% treatment inefficacy. Evident deficiencies of physician training: 52.4% (87/166) lacked systematic epilepsy training, and only 1.2% (2/166) had passed advanced EEG certification, resulting in only 19.3% (32/166) fully mastering epilepsy classification systems, while 31.9% demonstrated medication selection errors. Significant discrepancies in clinical decision‐making: 18.7% (31/166) of physicians inappropriately selected carbamazepine for juvenile absence epilepsy, while 3.6% (6/166) adopted a high‐risk immediate medication switching strategy. Fragmented patient management: 8.4% of physicians did not provide health education, and 59.0% (98/166) cited poor family adherence due to insufficient disease awareness. The regional referral rates varied widely (median: 17.5%, IQR: 35–5%). Significance: Tertiary hospitals undertake the main clinical burden but lack the construction of specialized infrastructure; lagging staff training leads to undermining the standardization of diagnosis and management; and the problem of the lack of systematic solutions in patient management persists. To enhance the overall service delivery, there are some proposed solutions including establishing hierarchical diagnosis and treatment networks, enhancing specialist training, and implementing regional quality control systems.